Dia Medica Therapeutics Inc. DMAC
We take great care to ensure that the data presented and summarized in this overview for DiaMedica Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DMAC
View all-
Vanguard Group Inc Valley Forge, PA1.35MShares$6.11 Million0.0% of portfolio
-
First Manhattan CO New York, NY606KShares$2.74 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX600KShares$2.71 Million5.72% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA557KShares$2.52 Million0.0% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.73 Million0.5% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny337KShares$1.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA316KShares$1.43 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL177KShares$801,3050.0% of portfolio
-
Jacob Asset Management Of New York LLC Hermosa Beach, CA169KShares$762,6590.62% of portfolio
-
Lpl Financial LLC Fort Mill, SC155KShares$701,9550.0% of portfolio
Latest Institutional Activity in DMAC
Top Purchases
Top Sells
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at DMAC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 07
2025
|
Richard D. Pilnik Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+7.12%
|
$48,000
$2.11 P/Share
|
|
Feb 13
2025
|
Randall Michael Giuffre Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+2.13%
|
$34,000
$2.88 P/Share
|
|
Jan 02
2025
|
James T. Parsons Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,917
+17.34%
|
$79,585
$5.34 P/Share
|
|
Jan 02
2025
|
Randall Michael Giuffre Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,861
+2.81%
|
$54,305
$5.34 P/Share
|
|
Jan 02
2025
|
Richard Kuntz Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,925
+29.08%
|
$49,625
$5.34 P/Share
|
|
Jan 02
2025
|
Richard D. Pilnik Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,393
+3.47%
|
$51,965
$5.34 P/Share
|
|
Jan 02
2025
|
Charles Pauling Semba Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,290
+10.6%
|
$26,450
$5.34 P/Share
|
|
Jun 28
2024
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+18.69%
|
$2,400,000
$2.5 P/Share
|
|
Jun 28
2024
|
Thomas Von Koch > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+17.84%
|
$2,400,000
$2.5 P/Share
|
|
Jan 02
2024
|
Charles Pauling Semba Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+19.25%
|
$18,750
$2.8 P/Share
|
|
Jan 02
2024
|
Richard Kuntz Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,285
+50.0%
|
$28,570
$2.8 P/Share
|
|
Jan 02
2024
|
Richard D. Pilnik Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,357
+9.83%
|
$60,714
$2.8 P/Share
|
|
Jan 02
2024
|
James T. Parsons Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,428
+26.34%
|
$42,856
$2.8 P/Share
|
|
Jan 02
2024
|
Randall Michael Giuffre Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,196
+5.0%
|
$38,392
$2.8 P/Share
|
|
Nov 16
2023
|
David J. Wambeke Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+3.66%
|
$40,000
$2.46 P/Share
|
|
Jun 23
2023
|
Thomas Von Koch > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,470,588
+25.37%
|
$4,411,764
$3.4 P/Share
|
|
Jun 23
2023
|
Randall Michael Giuffre Director |
SELL
Bona fide gift
|
Direct |
15,000
-4.16%
|
-
|
|
Jun 23
2023
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
65,000
+15.28%
|
$195,000
$3.91 P/Share
|
|
Jun 23
2023
|
Dietrich John Pauls President & CEO |
BUY
Open market or private purchase
|
Direct |
12,787
+15.71%
|
$38,361
$3.91 P/Share
|
|
Jun 23
2023
|
Charles Pauling Semba Director |
BUY
Open market or private purchase
|
Direct |
12,787
+29.93%
|
$38,361
$3.91 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 52.4K shares |
|---|---|
| Exercise of conversion of derivative security | 41K shares |